# Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

> **NCT03829020** · PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 9 (actual)

## Conditions studied

- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Metformin Hydrochloride
- **DRUG:** Nelfinavir Mesylate

## Key facts

- **NCT ID:** NCT03829020
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-17
- **Primary completion:** 2022-09-21
- **Final completion:** 2023-11-24
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2024-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03829020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03829020, "Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03829020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*